Analysts Conflicted on These Healthcare Names: Cara Therapeutics (NASDAQ: CARA) and Galapagos NV (NASDAQ: GLPG)

By Ryan Adsit

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cara Therapeutics (NASDAQ: CARA) and Galapagos NV (NASDAQ: GLPG).

Cara Therapeutics (NASDAQ: CARA)

In a report issued on June 21, Annabel Samimy from Stifel Nicolaus reiterated a Buy rating on Cara Therapeutics (NASDAQ: CARA), with a price target of $24. The company’s shares closed yesterday at $22.65, close to its 52-week high of $23.55.

According to TipRanks.com, Samimy is a 5-star analyst with an average return of 13.0% and a 54.6% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Corcept Therapeutics Inc, and Supernus Pharmaceuticals.

Currently, the analyst consensus on Cara Therapeutics is Strong Buy and the average price target is $27.57, representing a 21.7% upside.

In a report issued on June 21, Needham also reiterated a Buy rating on the stock with a $23 price target.
Galapagos NV (NASDAQ: GLPG)

Stifel Nicolaus analyst Adam Walsh reiterated a Hold rating on Galapagos NV (NASDAQ: GLPG) on June 21 and set a price target of $83. The company’s shares closed yesterday at $79.

According to TipRanks.com, Walsh is a 4-star analyst with an average return of 7.5% and a 48.0% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Reata Pharmaceuticals, and Aldeyra Therapeutics.

Galapagos NV has an analyst consensus of Moderate Buy, with a price target consensus of $96.33.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.